The I-SPY 2 trial did show an impressive improvement in pathological complete response rate in triple negative (60% vs 20%) and HR+/Her-2- breast cancer (34% vs 13%) with the addition of pembrolizumab to neoadjuvant chemotherapy, but we still don’t have long term data, such as disease free sur...

No. I agree with @Jairam Krishnamurthy—while pembrolizumab improved pathologic response rates in ISPY-2, we do not know the how this translates to longer term outcomes. This is important given the potential additional toxicity, including a 6% rate of adrenal insufficiency seen with pembrolizum...